Imiglucerase (Cerezyme)

Evicore covers Cerezyme (imiglucerase) only for Type 1 Gaucher disease and excludes off‑label uses and other Gaucher types. Coverage requires documented enzyme assay deficiency or genetic confirmation plus ≥1 clinical manifestation (anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly), is approved for 12 months, and prescribers must monitor for IgG antibody formation during the first year due to hypersensitivity risk.

"Cerezyme (imiglucerase) is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.